SCHEMBL1114899

SCHEMBL1114899

C=C1c2cc(OC)c(OC)cc2C(=O)C1c1ccncc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 3/20 0.47
MAPT P10636 3/20 0.47
SMN1; SMN2 Q16637 3/20 0.47
NPC1 O15118 2/20 0.47
TP53 P04637 2/20 0.47
MAPK10 P53779 1/20 0.47
GAA P10253 3/20 0.44
NPSR1 Q6W5P4 1/20 0.44
KMT2A Q03164 3/20 0.40
TSHR P16473 1/20 0.40
MEN1 O00255 2/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
PDE4D Q08499 5/20 0.38
ALDH1A1 P00352 2/20 0.38
PKM P14618 1/20 0.38
CA1 P00915 1/20 0.38
CA2 P00918 1/20 0.38
CA7 P43166 1/20 0.38
CA9 Q16790 1/20 0.38
PDE10A Q9Y233 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6274633 0.76 RAB9A (0.76) RAB9AMAPTSMN1; SMN2NPC1TP53
SCHEMBL12067057 0.66 MAOB (0.56) KMT2AMEN1ALDH1A1HPGDCYP19A1
SCHEMBL855370 0.65 RAB9A (1.00) RAB9AMAPTSMN1; SMN2NPC1TP53
SCHEMBL28015323 0.63 TLR8 (0.62) RAB9AMAPTSMN1; SMN2NPC1TP53
SCHEMBL4318498 0.62
SCHEMBL2423284 0.60 ERN1 (0.57) MAPTSMN1; SMN2TSHRALDH1A1HPGD
SCHEMBL7983584 0.59 PDE4D (0.47) SMN1; SMN2GAAKMT2AMEN1PDE4D
SCHEMBL6284499 0.59 RAB9A (0.74) RAB9AMAPTSMN1; SMN2NPC1TP53
SCHEMBL15741689 0.59 IMPDH2 (0.54) RAB9AMAPTNPC1GAATSHR
SCHEMBL31369142 0.59 CA1 (0.56) MAPTKMT2ATSHRMEN1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6953856-B2 Process for the preparation of 1-benzyl-4-(5,6-dimethoxy-1-indanon)-2-yl) methyl piperidine hydrochloride (Donepezil HCI) USV, LIMITED (IN) 2005-10-11 US claimed
US-20040158070-A1 Process for the preparation of 1-benzyl-4-(5,6-dimethoxy-1-indanon)-2-yl) methyl piperidine hydrochloride (Donepezil HCI) USV LIMITED, BSD MARG. (IN) 2004-08-12 US claimed
CN-110540520-B Method for purifying donepezil 迪嘉药业集团有限公司 2022-02-08 CN disclosed
CN-110540520-A Method for purifying donepezil WEIHAI DISU PHARMACEUTICAL CO LTD 2019-12-06 CN disclosed
EP-2278970-B1 PROCESS FOR THE PREPARATION OF DONEPEZIL HYDROCHLORIDE CIPLA LTD (IN) 2015-04-22 EP disclosed
EP-2278970-A1 PROCESS FOR THE PREPARATION OF DONEPEZIL HYDROCHLORIDE Cipla Limited (IN) 2011-02-02 EP disclosed
WO-2009118516-A1 PROCESS FOR THE PREPARATION OF DONEPEZIL HYDROCHLORIDE CIPLA LIMITED (GB) 2009-10-01 WO disclosed
WO-2008010235-A2 AN IMPROVED PROCESS FOR THE PREPARATION OF DONEPEZIL TORRENT PHARMACEUTICALS LIMITED (IN) 2008-01-24 WO disclosed
US-20070129549-A1 Stable lamotrigine pharmaceutical compositions and processes for their preparation RANBAXY LABORATORIES LIMITED (IN) 2007-06-07 US disclosed
EP-1531151-B1 A process for the preparation of 1-benzyl-4-¬(5,6-dimethoxy-1-indanon)-2-yl| methyl piperidine hydrochloride (donepezil hcl) USV LTD (IN) 2007-03-07 EP disclosed
EP-1608371-A1 PROCESS FOR THE PREPARATION OF DONEPEZIL AND DERIVATIVES THEREOF RANBAXY LABORATORIES, LTD. (IN) 2005-12-28 EP disclosed
US-6953856-B2 Process for the preparation of 1-benzyl-4-(5,6-dimethoxy-1-indanon)-2-yl) methyl piperidine hydrochloride (Donepezil HCI) USV, LIMITED (IN) 2005-10-11 US disclosed
EP-1531151-A1 A process for the preparation of 1-benzyl-4-[(5,6-dimethoxy-1-indanon)-2-yl] methyl piperidine hydrochloride (donepezil hcl) USV Limited (IN) 2005-05-18 EP disclosed
WO-2004082685-A1 PROCESS FOR THE PREPARATION OF DONEPEZIL AND DERIVATIVES THEREOF RANBAXY LABORATORIES LIMITED (IN) 2004-09-30 WO disclosed
US-20040158070-A1 Process for the preparation of 1-benzyl-4-(5,6-dimethoxy-1-indanon)-2-yl) methyl piperidine hydrochloride (Donepezil HCI) USV LIMITED, BSD MARG. (IN) 2004-08-12 US disclosed
US-6252081-B1 REDUCING OF THE COORRESPONDING QUATERNARY AMMONIUM SALT EISAI CO., LTD. (JP) 2001-06-26 US disclosed
EP-0711756-B1 Process for the production of benzyl-piperidylmethyl-indanone BAYER AG (DE) 1998-07-22 EP disclosed
US-5606064-A Process for the preparation of benzyl-piperidylmethyl-indanones BAYER AKTIENGESELLSCHAFT (DE) 1997-02-25 US disclosed
EP-0711756-A1 Process for the production of benzyl-piperidylmethyl-indanone BAYER AG (DE) 1996-05-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070129549-A1 Stable lamotrigine pharmaceutical compositions and processes for their preparation KCNJ1, KCNJ8, KCNJ2 RAB9A 3428/4885MAPT 86/4885SMN1; SMN2 1051/4885
US-20040158070-A1 Process for the preparation of 1-benzyl-4-(5,6-dimethoxy-1-indanon)-2-yl) methyl piperidine hydrochloride (Donepezil HCI) HCN1, HNMT, H1-5 RAB9A 3943/4885MAPT 697/4885SMN1; SMN2 2881/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.